ZNF583 and osteosarcoma: Our qRT-PCR analysis demonstrated that osteosarcoma cells expressed higher levels of CGNL1 and CXCL13 compared to osteoblast cells, while ZNF583 had the opposite effect, indicating its potential as a novel anti-oncogene (Fig. 7D–F).